美洛昔康与萘丁美酮双盲随机对照治疗类风湿关节炎

A double-blind,randomized controlled clinical study of meloxicam and nabumetone in the treatment of rheumatoid arthritis

目的 评价美洛昔康 /萘丁美酮治疗类风湿关节炎的疗效和安全性。方法 随机对照、双盲的比较研究。共完成病例12 0例 (美洛昔康 5 9例 ;萘丁美酮 6 1例 )。po美洛昔康 15mg每天一次或萘丁美酮 10 0 0mg每天一次 ,疗程 4周 ,其中 41例患者连用 8周。结果 4,8周时美洛昔康总有效率为 6 9.5 % ,95 .0 % ;萘丁美酮为 6 7.2 % ,90 .5 % ,两药均能显著改善患者的症状和体征 ,降低血沉。 8周时美洛昔康改善患者的休息痛和关节压痛指数两项优于萘丁美酮 (P <0 .0 5 )。安全性评价 :美洛昔康不良反应发生率 :10 .2 % ;萘丁美酮 18.0 % ,统计分析两药的耐受性无明显差异。不良反应以消化道症状为主 ,无因不良反应停药病例。

OBJECTIVE To evaluate the efficacy and safety of meloxicam and nabumetone in the treatment of patients with rheumatoid arthritis.METHODS Double-blind,randomized,controlled clinical trial of meloxicam versus nabumetone was performed.120 patients (59 versus 61) were given meloxicam po 15 mg·day -1 or nabumeone 1 000 mg·day -1 for 4 weeks,41 patients (20 versus 21) for 8 weeks.RESULTS Meloxicam and nabumetone improved the symptoms and signs of rheumatoid arthritis,decreased ESR.The total efficacy rates of meloxicam were 69.5% and 95.0%;and the nabumetone were 67.2% and 90.5%,after 4 weeks and 8 weeks treatment,respectively.The incidence of adverse effects was 10.2% for meloxicam and 18.0% for nabumetone.Main adverse effects were symptoms of gastrointestinal tract.All adverse effects of both drugs were mild and none ceased treatment.CONCLUSION Meloxicam appeared to be effective and safe in the treatment of rheumatoid arthritis,compared with nabumetone without significant difference.